Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib response and JAK/STAT signature in refractory rheumatoid arthritis
2021-001560-14Phase 4Active
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib in rheumatoid arthritis (RA), sponsored by Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz. Primary endpoint: Clinical response to tofacitinib at 12 weeks and association with JAK/STAT synovial signature. Started Jun 2021; status: active.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-001560-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001560-14.